BCTXNasdaqPharmaceutical PreparationsFiscal year ends July 31Also trades as BCTXL, BCTXZ

BriaCell Therapeutics Corp.

Financials through Q3 FY2026, quarter ended Apr 30, 2026Last filing: 10-Q on Jun 9, 2026

$3.38−0.02 (-0.59%)

Close on Oct 19, 2026

Market cap: $24.51M
P/E (TTM): –
Dividend yield: –

BriaCell Therapeutics Corp. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-07-31	FY 2024 2024-07-31	FY 2023 2023-07-31	FY 2022 2022-07-31	FY 2021 2021-07-31	FY 2020 2020-07-31	FY 2019 2019-08-01	FY 2018 2018-07-31
Cash & Equivalents	10	0.86	21	41	57	0.02	0.76	–
Short-Term Investments	7.37	–	–	–	–	–	–	–
Cash & Short-Term Investments	18	0.86	21	41	57	0.02	0.76	–
Receivables	–	–	0.02	0.02	0.01	0.02	0.00	–
Prepaid Expenses & Other	1.39	1.32	4.84	1.28	0.52	–	–	–
Total Current Assets	20	3.65	27	42	58	0.26	0.17	–
Property, Plant & Equipment	0.30	0.39	0.00	0.00	–	–	–	–
Gross Property, Plant & Equipment	–	0.46	–	–	–	–	–	–
Equity Method Investments	–	–	0.00	0.00	0.00	–	–	–
Intangible Assets	0.18	0.20	0.22	0.23	0.25	0.26	0.28	–
Deferred Tax Assets	–	–	–	–	0.06	0.05	–	–
Total Assets	22	5.87	27	43	58	0.52	0.44	–
Accounts Payable	–	–	–	–	0.56	3.71	0.81	–
Total Current Liabilities	3.98	7.46	1.80	0.94	0.56	3.96	1.13	–
Deferred Tax Liabilities	–	–	–	–	0.06	0.05	–	–
Total Liabilities	4.32	8.56	31	32	30	3.26	1.13	–
Common Stock	102	72	70	66	55	12	11	–
Additional Paid-In Capital	–	–	7.42	5.23	2.18	–	–	–
Retained Earnings	-112	-85	-81	-60	-29	-18	-15	–
Comprehensive Income & Other	-0.14	-0.14	-0.14	-0.14	-0.14	–	–	–
Shareholders' Equity	–	–	-3.78	10	28	-2.74	–	–
Noncontrolling Interest	-0.55	-0.30	–	–	–	–	–	–
Total Equity	17	-2.68	-3.78	10	28	-2.74	-0.69	1.00
Total Liabilities & Equity	22	5.87	27	43	58	0.52	0.44	–
Shares Outstanding(shares)	1.88	0.12	0.11	0.10	0.10	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Apr 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 7.07
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 191.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –